|
Mar 31
|
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial
|
|
Mar 29
|
Why Merck & Co. Inc. (MRK) Went Up On Friday?
|
|
Mar 28
|
China Expansion Helps Fuel This AI-Powered Cloud Stock In Rough Market
|
|
Mar 28
|
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda
|
|
Mar 27
|
Is Merck & Co. (MRK) the Low Volatility Stock to Buy According to Billionaire Ken Fisher?
|
|
Mar 27
|
Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?
|
|
Mar 27
|
Merck releases positive data for blockbuster cancer drug
|
|
Mar 27
|
Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
|
|
Mar 27
|
Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form
|
|
Mar 27
|
Here is Why Jim Cramer Is Bullish About Merck (MRK)
|
|
Mar 26
|
Is Merck & Co., Inc. (MRK) the Best Consistent Dividend Stock to Buy?
|
|
Mar 26
|
Jim Cramer on Merck (MRK): “I Like It at This Level – But I Like Bristol-Myers Even More!”
|
|
Mar 26
|
Merck (NYSE:MRK) Gains EC Approval For CAPVAXIVE® Amid Recent 7% Share Price Dip
|
|
Mar 26
|
European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
|
|
Mar 16
|
Merck & Co., Inc. (MRK): Among Top Dividend Contenders List
|
|
Mar 13
|
MSD to push for approval of HIV combo after Phase III success
|
|
Mar 13
|
Merck & Co., Inc. (NYSE:MRK) Looks Interesting, And It's About To Pay A Dividend
|
|
Mar 12
|
Why Merck & Co., Inc. (MRK) is the Best Pharma Stock to Buy According to Hedge Funds
|
|
Mar 12
|
Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025
|
|
Mar 12
|
Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
|